These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32004486)

  • 1. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
    Tambaro FP; Wierda WG
    Lancet Haematol; 2020 Feb; 7(2):e168-e176. PubMed ID: 32004486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
    Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
    Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
    Gribben JG
    Br J Haematol; 2020 Mar; 188(6):844-851. PubMed ID: 31858596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.
    Fischer K; Al-Sawaf O; Hallek M
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):357-362. PubMed ID: 33275717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
    Crombie J; Davids MS
    Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
    Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
    Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
    Diao S; Nichols ED; DiNardo C; Konopleva M; Ning J; Qiao W; Maiti A; DiPippo AJ
    Am J Hematol; 2021 Mar; 96(3):E65-E68. PubMed ID: 33259075
    [No Abstract]   [Full Text] [Related]  

  • 11. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
    Cozad M; Stump SE; Buhlinger K; Collins J; Muir M; Coombs CC; Muluneh B
    Leuk Lymphoma; 2022 Aug; 63(8):1831-1838. PubMed ID: 35262457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
    Daniel C; Mato AR
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
    Cheng FM; Tien JZ; Chen TT; Yeh SP; Lin CC
    Ann Hematol; 2020 Sep; 99(9):2193-2195. PubMed ID: 32621180
    [No Abstract]   [Full Text] [Related]  

  • 16. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
    Lampson BL; Davids MS
    Curr Hematol Malig Rep; 2017 Feb; 12(1):11-19. PubMed ID: 28116634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare].
    Burghi G; Berrutti D; Manzanares W
    Med Intensiva; 2011 Apr; 35(3):170-8. PubMed ID: 21112673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
    Bose P; Qubaiah O
    J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.